BactiQuant (BACTIQ) investor relations material

Executive summary

• Revenue for H1 2026 reached DKK 5.3 million, a 29% increase year-over-year, driven by strong recurring revenue, especially in Pharma.

• EBITDA improved to DKK -3.7 million from DKK -5.6 million in H1 2025, and net loss before tax narrowed to DKK -4.8 million from DKK -6.9 million.

• Cash position at June 30, 2026 was DKK 11.9 million, up from DKK 7.8 million a year earlier.

• Equity increased to DKK 12.5 million from DKK 8.0 million at June 30, 2025.

Financial highlights

• Gross margin turned positive at DKK 0.7 million versus negative DKK 0.9 million in H1 2025.

• Operating loss (EBIT) improved to DKK -4.4 million from DKK -6.4 million year-over-year.

• Result per share was DKK -0.13 compared to DKK -0.24 in H1 2025.

• Cash flow from operations improved, with period-end cash up by DKK 4.1 million year-over-year.

Outlook and guidance

• 2026 revenue guidance maintained at DKK 10–13 million, with expected EBITDA between DKK -7 and -10 million.

• Liquidity is expected to be sufficient until mid-2027, supported by recent cost savings and preliminary 2027 forecasts.